S. 2426 · 119th Congress · Health
Equitable Community Access to Pharmacist Services Act
- IntroducedJul 24, 2025 Done
- CommitteeReferred to Finance Current stage
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill provides for permanent coverage under Medicare of certain pharmacist services.
Specifically, the bill provides for permanent coverage of testing and treatment services provided by pharmacists relating to (1) COVID-19, influenza, respiratory syncytial virus (RSV), and streptococcal pharyngitis (strep throat); and (2) other public health needs in relation to a declared public health emergency. (Similar authorities were temporarily granted during the COVID-19 public health emergency.) Such services must be provided in accordance with the applicable state laws governing pharmacists' scope of practice.
Congressional Research Service · summary of “Introduced in Senate” version · Jul 24, 2025
Who lobbies on it
21 organizations, more than 99% of Senate bills · 101 filings · Q3 2025–Q3 2026These 21 organizations’ PACs gave $441K to 22 of the 32 members sponsoring or cosponsoring S. 2426 in the 2025–26 election cycle.
One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
American Medical Association
5 of 5 quarters
“Issues related to Physician Fee Schedule and physician payment reform; H.R. 879, Medicare Patient Access and Practice Stabilization Act; H.R. 3164/S. 2426, Equitable Community Access to Pharmacist Services Act; H.R. 8163/S. 5180, Provider Reimbursement Stability Act; Issues related to Provider Reimbursement Stability…”
$17.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Cvs Health (and Subsidiaries)
5 of 5 quarters
“Issues related to retail pharmacy, drug pricing, and women's health. H.R. 3164 - The Main Street Pharmacy Access Act S. 2426 - The Equitable Community Access to Pharmacist Services Act H.R. 5031, The Preserving Patient Access to Long-Term Care Pharmacies Act”
$8.9M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Walmart Inc
5 of 5 quarters
“Discussions regarding H.R.3164/S.2426, Main Street Pharmacy Access Act Discussions related to S.2355, the Patients Deserve Price Tags Act Discussions related to Walmart's health and wellness business and priorities Discussions regarding employee benefits innovations”
$7.2M lobbying spend in 2026 to date, all issuesQ3 2026 filing
18 more organizations, every filingPROUpgrade
Organizations that named S. 2426 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Jul 24, 2025Read twice and referred to the Committee on Finance. (text: CR S4701)
- Jul 24, 2025Introduced in Senate